NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients

BACKGROUND: Trastuzumab is a drug used in HER2-positive breast cancer that increases patient survival. Due to cardiotoxicity is the most important side effect of trastuzumab treatment, cardiac monitoring should be a priority. The purpose of this study is to evaluate plasma NT-proBNP level and major...

Descripción completa

Detalles Bibliográficos
Autores principales: Blancas, Isabel, Martín-Pérez, Francisco J., Garrido, José M., Rodríguez-Serrano, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511727/
https://www.ncbi.nlm.nih.gov/pubmed/32977298
http://dx.doi.org/10.1016/j.breast.2020.09.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511727/
https://www.ncbi.nlm.nih.gov/pubmed/32977298
http://dx.doi.org/10.1016/j.breast.2020.09.001

Ejemplares similares